secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-10-13T10:01:58+00:00
Accession:  0001437749-26-032465
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ImmuCell preliminary Q3 2026 sales $8.0M, up 46% YoY; nine-month sales $25.6M, up 27.8%
--------------------------------------------------------------------------------

- Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase over Q3 2025; domestic sales were $6.9 million, up 29.2%.
- Nine-month 2026 sales were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.
- Growth was broad-based: Tri-Shield rose 51% over Q3 2025, Dual-Force 36%, and the recently launched functional feed line 37%.
- CFO Timothy Fiori said the comparison was aided by depressed Q3 2025 sales caused by high distributor purchases in Q2 2025.
- ImmuCell will discontinue early sales reporting; CEO Olivier te Boekhorst will discuss full Q3 results on a call November 13, 2026 at 9:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/0001437749-26-032465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/iccc20261009_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer